Zhangzhou Pientzehuang Pharmaceutical., Ltd

XSSC:600436 Stock Report

Market Cap: CN¥138.1b

Zhangzhou Pientzehuang Pharmaceutical Valuation

Is 600436 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600436 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600436 (CN¥226.5) is trading above our estimate of fair value (CN¥223.74)

Significantly Below Fair Value: 600436 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600436?

Other financial metrics that can be useful for relative valuation.

600436 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue13x
Enterprise Value/EBITDA38.9x
PEG Ratio2.8x

Price to Earnings Ratio vs Peers

How does 600436's PE Ratio compare to its peers?

The above table shows the PE ratio for 600436 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.2x
000538 Yunnan Baiyao GroupLtd
22.2x9.7%CN¥96.6b
688506 Sichuan Biokin PharmaceuticalLtd
18.6x-68.8%CN¥82.5b
600085 Beijing Tongrentang
35.3x14.1%CN¥60.6b
000999 China Resources Sanjiu Medical & Pharmaceutical
20.6x12.6%CN¥64.3b
600436 Zhangzhou Pientzehuang Pharmaceutical
45.5x16.0%CN¥138.1b

Price-To-Earnings vs Peers: 600436 is expensive based on its Price-To-Earnings Ratio (45.5x) compared to the peer average (24.2x).


Price to Earnings Ratio vs Industry

How does 600436's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.7%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.7%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 600436 is expensive based on its Price-To-Earnings Ratio (45.5x) compared to the CN Pharmaceuticals industry average (28x).


Price to Earnings Ratio vs Fair Ratio

What is 600436's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600436 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio45.5x
Fair PE Ratio35.9x

Price-To-Earnings vs Fair Ratio: 600436 is expensive based on its Price-To-Earnings Ratio (45.5x) compared to the estimated Fair Price-To-Earnings Ratio (35.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 600436 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥228.97
CN¥285.76
+24.8%
16.0%CN¥358.00CN¥190.00n/a10
Jun ’25CN¥227.00
CN¥277.73
+22.3%
14.7%CN¥328.00CN¥190.00n/a9
May ’25CN¥237.24
CN¥285.63
+20.4%
15.7%CN¥336.00CN¥190.00n/a9
Apr ’25CN¥234.42
CN¥295.86
+26.2%
14.4%CN¥336.00CN¥195.00n/a10
Mar ’25CN¥223.36
CN¥295.86
+32.5%
14.4%CN¥336.00CN¥195.00n/a10
Feb ’25CN¥191.21
CN¥299.86
+56.8%
12.5%CN¥336.00CN¥202.00n/a10
Jan ’25CN¥241.99
CN¥302.86
+25.2%
13.2%CN¥350.00CN¥202.00n/a10
Dec ’24CN¥252.11
CN¥302.86
+20.1%
13.2%CN¥350.00CN¥202.00n/a10
Nov ’24CN¥251.20
CN¥302.86
+20.6%
13.2%CN¥350.00CN¥202.00n/a10
Oct ’24CN¥275.21
CN¥315.40
+14.6%
13.3%CN¥370.00CN¥200.00n/a11
Sep ’24CN¥278.03
CN¥315.40
+13.4%
13.3%CN¥370.00CN¥200.00n/a11
Aug ’24CN¥289.78
CN¥318.22
+9.8%
14.7%CN¥390.00CN¥205.00n/a10
Jul ’24CN¥286.36
CN¥320.80
+12.0%
14.9%CN¥390.00CN¥210.00n/a9
Jun ’24CN¥298.00
CN¥319.68
+7.3%
15.7%CN¥390.00CN¥200.00CN¥227.009
May ’24CN¥271.93
CN¥305.26
+12.3%
15.6%CN¥358.00CN¥200.00CN¥237.249
Apr ’24CN¥284.38
CN¥302.09
+6.2%
18.8%CN¥360.00CN¥200.00CN¥234.427
Mar ’24CN¥314.58
CN¥328.32
+4.4%
28.4%CN¥550.00CN¥200.00CN¥223.369
Feb ’24CN¥311.14
CN¥328.88
+5.7%
28.1%CN¥550.00CN¥205.00CN¥191.219
Jan ’24CN¥288.46
CN¥324.43
+12.5%
28.3%CN¥550.00CN¥205.00CN¥241.999
Dec ’23CN¥258.99
CN¥329.98
+27.4%
28.4%CN¥550.00CN¥205.00CN¥252.119
Nov ’23CN¥242.63
CN¥331.23
+36.5%
30.0%CN¥550.00CN¥205.00CN¥251.208
Oct ’23CN¥266.80
CN¥368.45
+38.1%
25.1%CN¥550.00CN¥235.00CN¥275.217
Sep ’23CN¥298.30
CN¥368.45
+23.5%
25.1%CN¥550.00CN¥235.00CN¥278.037
Aug ’23CN¥293.55
CN¥347.43
+18.4%
21.1%CN¥460.50CN¥245.00CN¥289.785
Jul ’23CN¥350.78
CN¥356.76
+1.7%
20.0%CN¥460.50CN¥256.00CN¥286.365
Jun ’23CN¥304.05
CN¥411.71
+35.4%
25.7%CN¥550.00CN¥256.00CN¥298.007

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.